These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 11404194)

  • 21. Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP).
    Carreño V; Marcellin P; Hadziyannis S; Salmerón J; Diago M; Kitis GE; Vafiadis I; Schalm SW; Zahm F; Manzarbeitia F; Jiménez FJ; Quiroga JA
    Hepatology; 1999 Jul; 30(1):277-82. PubMed ID: 10385667
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thymosin alpha 1 in combination with interferon alpha and ribavirin in chronic hepatitis C patients who are non-responders or relapsers to interferon alpha plus ribavirin.
    Abbas Z; Hamid SS; Tabassum S; Jafri W
    J Pak Med Assoc; 2004 Nov; 54(11):571-4. PubMed ID: 15623184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group.
    Kasahara A; Hayashi N; Mochizuki K; Takayanagi M; Yoshioka K; Kakumu S; Iijima A; Urushihara A; Kiyosawa K; Okuda M; Hino K; Okita K
    Hepatology; 1998 May; 27(5):1394-402. PubMed ID: 9581697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study.
    Barbaro G; Di Lorenzo G; Soldini M; Giancaspro G; Bellomo G; Belloni G; Grisorio B; Annese M; Bacca D; Francavilla R; Rizzo G; Barbarini G
    Am J Gastroenterol; 1998 Dec; 93(12):2445-51. PubMed ID: 9860407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interferon-alpha suppresses liver cell proliferation in patients with chronic hepatitis C virus infection.
    Donato MF; Degott C; Arosio E; Martinot M; Monti V; Morabito A; Marcellin P; Colombo M
    J Viral Hepat; 2005 Sep; 12(5):499-506. PubMed ID: 16108765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.
    Tanaka H; Tsukuma H; Kasahara A; Hayashi N; Yoshihara H; Masuzawa M; Kanda T; Kashiwagi T; Inoue A; Kato M; Oshima A; Kinoshita Y; Kamada T
    Int J Cancer; 2000 Sep; 87(5):741-9. PubMed ID: 10925370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection.
    Jessner W; Stauber R; Hackl F; Datz C; Watkins-Riedel T; Hofer H; Gangl A; Kessler H; Ferenci P
    J Viral Hepat; 2003 Jan; 10(1):37-42. PubMed ID: 12558910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retreatment of chronic hepatitis C: who and how?
    Heathcote J
    Liver Int; 2009 Jan; 29 Suppl 1():49-56. PubMed ID: 19207966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Viral and host factors in determining response of relapsers with chronic hepatitis C to retreatment with interferon.
    Almasio PL; Di Marco V; Bonura C; Fuschi P; Camma C; Lo Iacono O; Artini M; Natoli C; Di Stefano R; Levrero M; Craxi A
    Dig Dis Sci; 1999 May; 44(5):1013-9. PubMed ID: 10235612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. alpha-Interferon retreatment of patients with chronic hepatitis C.
    Rabinovitz M; Block G; Finkelstein SD
    Am J Gastroenterol; 1996 Aug; 91(8):1523-6. PubMed ID: 8759654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Retreatment options for patients with chronic hepatitis C].
    Hrstić I; Ostojić R; Vucelić B
    Acta Med Croatica; 2009 Dec; 63(5):417-22. PubMed ID: 20198901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pilot study of interferon-alpha high-dose induction therapy in combination with ribavirin plus amantadine for nonresponder patients with chronic hepatitis C.
    Berg T; Naumann U; Wiedenmann B; Hopf U
    Z Gastroenterol; 2001 Feb; 39(2):145-51. PubMed ID: 11253505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High dosage alpha-interferon for treatment of children and young adults with chronic hepatitis C disease.
    Marcellini M; Kondili LA; Comparcola D; Spada E; Sartorelli MR; Palumbo M; Rapicetta M
    Pediatr Infect Dis J; 1997 Nov; 16(11):1049-53. PubMed ID: 9384338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Value of high-dose interferon-alpha in chronic viral hepatitis C patients non-responder to a 1st treatment. Pilot study prospective and randomized trial].
    Rolachon A; Kézachian G; Causse X; Baud M; Leroy V; Maynard-Muet M; Pasquier D; Zarski JP
    Gastroenterol Clin Biol; 1997; 21(12):924-8. PubMed ID: 9587555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy.
    Moriyama M; Matsumura H; Aoki H; Shimizu T; Yamagami H; Shioda A; Kaneko M; Goto I; Tanaka N; Arakawa Y
    Liver Int; 2005 Feb; 25(1):85-90. PubMed ID: 15698403
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Retreatment with interferon of relapsed chronic hepatitis C patients].
    Li MH; Xie Y; Zhao H; Ou WN; Xu DZ; Lu ZM; Luo KX; Jia JD; Wang YM; Zhao GZ; Zhang SL; Zhang DZ
    Zhonghua Gan Zang Bing Za Zhi; 2006 Jan; 14(1):3-6. PubMed ID: 16420755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interferon-alpha-2b and ribavirin for retreatment of chronic hepatitis C.
    Dettmer RM; Reinus JF; Clain DJ; Aytaman A; Levendoglu H; Bloom AA; Isaacson MP; Spinnell M; Meyer D; Sarabanchong V; Zhang Y; Garcia-Carrasquillo RJ; Markowitz DD; Magun AM; Worman HJ
    Hepatogastroenterology; 2002; 49(45):758-63. PubMed ID: 12063985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term lymphoblastoid interferon-alpha therapy for non-cirrhotic chronic hepatitis C: an Italian multicentre study on dose and duration of IFN alpha treatment.
    Piccinino F; Felaco FM; Sagnelli E; Aprea L; Messina V; Pasquale G; Filippini P; Scolastico C
    Res Virol; 1998; 149(5):283-91. PubMed ID: 9879606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C. The Consensus Interferon Study Group.
    Lee WM; Reddy KR; Tong MJ; Black M; van Leeuwen DJ; Hollinger FB; Mullen KD; Pimstone N; Albert D; Gardner S
    Hepatology; 1998 Nov; 28(5):1411-5. PubMed ID: 9794929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical characteristics of patients with chronic hepatitis C showing biochemical remission, without hepatitis C virus eradication, as a result of interferon therapy. The Osaka Liver Disease Study Group.
    Kasahara A; Hayashi N; Mochizuki K; Hiramatsu N; Sasaki Y; Kakumu S; Kiyosawa K; Okita K
    J Viral Hepat; 2000 Sep; 7(5):343-51. PubMed ID: 10971822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.